The Institute of Bioengineering and Bioimaging (IBB) is located in Singapore's research and development hub for biomedical sciences, at the heart of Biopolis. The institute is located at Helios and Nanos and is staffed by imaging experts, bioengineers, chemists, physicists, biologists and clinicians. IBB integrates the capabilities and technologies built up by the Institute of Bioengineering and Nanotechnology (IBN) and Singapore Bioimaging Consortium (SBIC), which were established in 2003 and 2004 respectively. IBB's work includes the following scientific breakthroughs and innovations:
- High-impact papers in leading scientific journals
- Active patents under the Biomedical Research Council’s portfolio
- 10 spin-off companies (such as Lucence, InvitroCue and Respiree)
IBB's VisionTo be a world-leading Bioengineering
and Bioimaging Institute focused on the translation of technologies for
the benefit of human and society.
IBB's MissionThe
Institute of Bioengineering & Bioimaging strives to develop new
technologies and engineering solutions addressing health, medical and
sustainability challenges and to promote the advancement of disease
prevention, diagnosis and therapy. With our comprehensive research
capabilities at the interface of physical sciences, engineering and
bioimaging, the institute brings together multi-disciplinary teams of
leading scientists and engineers to tackle national and international
health and technological priorities through partnership with both
clinical and industry communities.
IBB spearheads multi-disciplinary, application-driven research at the interface of biology, chemistry, engineering and medicine, and work closely with stakeholders across the ecosystem to deliver innovative solutions in strategic areas such as cancer, infectious diseases, and food and nutrition.